Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial - Scorecard - MDSpire
Advertisement
Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial
Clinical Scorecard: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of Apitegromab for Preserving Lean Mass During Weight Loss Induced by Tirzepatide
At a Glance
Category
Detail
Condition
Weight loss during incretin mimetic therapy
Key Mechanisms
Inhibition of myostatin to preserve lean mass
Target Population
Adults with overweight or obesity receiving incretin mimetic therapy
Care Setting
Multicenter clinical trial
Key Highlights
Apitegromab significantly reduced lean mass loss compared to placebo.
Lean mass loss was preserved by 1.9 kg with apitegromab versus 3.5 kg with placebo.
Total body weight loss was similar between both groups.
Apitegromab treatment resulted in a relative retention of 54.9% lean mass.
Safety profile was comparable between apitegromab and placebo.
Guideline-Based Recommendations
Diagnosis
Evaluate overweight or obesity in adults receiving incretin mimetic therapy.
Management
Consider apitegromab for preserving lean mass during weight loss.
Monitoring & Follow-up
Monitor lean mass and body composition changes during treatment.
Risks
Monitor for gastrointestinal adverse events, including nausea and fatigue.
Patient & Prescribing Data
Adults with overweight or obesity on tirzepatide therapy.
Apitegromab may help mitigate lean mass loss during weight management.
Clinical Best Practices
Incorporate lean mass preservation strategies in weight loss management.
Assess patient response to apitegromab in conjunction with tirzepatide.
by Richard E. Pratley, Douglas Scott Denham, Rupal Trivedi, Elaine Watkins, Lisa Connery, Jennifer Barnes, Dongzi Yu, Janet Hong, Christopher Simard, Kimberly Umans, Lan Liu, Giridhar S. Tirucherai, Jing L. Marantz
Mendelian randomization analyses linked higher birthweight with greater mid-childhood height but the connection could reflect genetic factors related to skeletal growth.
